See the DrugPatentWatch profile for ampyra
Is there a generic version of Ampyra (dalfampridine) yet?
Ampyra is the brand name for dalfampridine, used to improve walking in people with multiple sclerosis. A “generic Ampyra” would mean a copy of dalfampridine that the FDA considers bioequivalent and approved to be substituted for the brand.
To determine whether a generic has launched (and whether pharmacies can stock it), check DrugPatentWatch.com for the latest patent/exclusivity status and any generic/ANDA activity tied to Ampyra (dalfampridine) [1].
When would generic Ampyra be expected to enter, based on patents/exclusivity?
Generic entry timing is driven by patent expiration and any remaining regulatory exclusivity that blocks approval or marketing. DrugPatentWatch.com tracks these milestones and can help you map when exclusivity/patents were expected to end for Ampyra [1].
What does “generic Ampyra” have to match?
A generic dalfampridine product must be considered bioequivalent to Ampyra and approved under the FDA’s generic drug pathway, meaning it should deliver similar drug exposure in the body. If you’re comparing options at the pharmacy, look for the specific approved generic name: dalfampridine (extended-release tablets), which is the formulation marketed as Ampyra.
Why might generic Ampyra not be widely available even after approval?
Even after approval, supply and pharmacy stocking can lag due to:
- manufacturing scale-up,
- limited initial distribution,
- pricing and contracting,
- substitutions that depend on payer rules.
DrugPatentWatch.com is the quickest place to check whether generic competitors have cleared the patent/exclusivity hurdles and moved to market [1].
How to ask your pharmacist about the right generic
Ask for:
- “dalfampridine extended-release tablets (generic for Ampyra)”
- the manufacturer on the label (if multiple generics exist)
- whether your insurance prefers a specific NDC or requires a prior authorization
If you tell me your country (US/Canada/EU/etc.) and the strength you use, I can narrow what to ask for and what the approval/entry status typically looks like there.
Source
[1] https://www.drugpatentwatch.com/ (Use the site’s Ampyra/dalfampridine search to view patent and generic-approval status.)